#Digital PCR (dPCR) and Real-time PCR (qPCR) Market Share

[mitalipingale]

https://app.socie.com.br/read-blog/154633_digital-pcr-dpcr-and-real-time-pcr-qpcr-market-share-overview-competitive-analys.html

The Digital PCR (dPCR) and Real-time PCR (qPCR) Market in 2023 is US$ 8.5 billion, and is expected to reach US$ 15.76 billion by 2031 at a CAGR of 8.00%.

[research-89]

https://cynochat.com/read-blog/175004_digital-pcr-dpcr-and-real-time-pcr-qpcr-market-overview-size-share-and-forecast.html

[healthcareindustryresearch]

What Is Driving the Global Digital PCR and qPCR Market Toward $14.8 Billion by 2029?

The Strategic Shift in Precision Diagnostics

The global Digital PCR (dPCR) and Real-Time PCR (qPCR) market is poised for strong and sustained growth, rising from US$9.4 billion in 2023 to a projected US$14.8 billion by 2029, advancing at a CAGR of 8.1%. This dynamic expansion is no accident—it reflects a broader shift in how global healthcare systems approach diagnostics, disease management, and therapeutic development.

Fueled by precision medicine, the surge in infectious diseases, and the demand for faster, more reliable diagnostic solutions, dPCR and qPCR technologies are becoming indispensable. But the market also faces distinct structural and strategic hurdles. In this blog, we explore what’s really powering this market, where growth is concentrated, and how stakeholders—from diagnostics firms to pharma executives—can capitalize.

Download PDF Brochure

Why Is the Digital PCR and qPCR Market Gaining Momentum?

1. Rising Burden of Infectious and Genetic Diseases With the global rise in infectious diseases (like COVID-19 and its variants), tuberculosis, and rare genetic disorders, there's a mounting demand for high-sensitivity diagnostics. Both dPCR and qPCR offer fast turnaround, accurate pathogen quantification, and early detection—critical tools in combating outbreaks and managing chronic conditions.

2. Strategic Role in Biomarker Discovery As precision medicine moves into the mainstream, biomarker-driven diagnostics are becoming foundational. Real-time PCR is essential for gene expression studies, while dPCR provides absolute quantification, enabling more accurate companion diagnostics. The techniques are widely used in clinical trials, personalized therapy development, and oncology diagnostics.

3. Point-of-Care (PoC) Evolution qPCR and dPCR technologies are increasingly integrated into portable, PoC diagnostic platforms, allowing testing in non-laboratory settings such as rural clinics or emergency departments. This shift addresses global healthcare inequities and strengthens pandemic preparedness.

Where Are the Highest-Growth Opportunities?

Asia Pacific: The Fastest Growing Region

Asia Pacific is emerging as a hotbed of growth, thanks to:

Expanding pharma-biotech R&D in India, China, and South Korea

Heavy investment by CMOs and CDMOs

Government initiatives supporting molecular diagnostics

A large untapped market for PoC applications and cancer screening tools

However, instrument affordability and reimbursement gaps remain challenges that must be addressed to unlock full potential.

North America: The Market Leader

North America commands the largest share, led by:

Presence of dominant players like Thermo Fisher Scientific, Bio-Rad, and Danaher Corporation

Mature regulatory landscape supporting innovative diagnostics

High adoption of PCR in clinical diagnostics, biotech, and public health surveillance

How Do Instrument Innovations Drive Market Leadership?

Among instruments, droplet digital PCR (ddPCR) is leading the digital PCR sub-segment. Its ability to partition reactions into thousands of droplets, each acting as a mini PCR reaction, offers:

High precision

Inhibitor tolerance

Quantification without need for standard curves

This makes it ideal for oncology, liquid biopsy, viral load monitoring, and cell therapy R&D.

Who Are the Key Stakeholders in the Market Ecosystem?

The ecosystem spans multiple nodes:

Stakeholder

Role

Raw Material Suppliers

Reagents, enzymes, and microfluidics components

Instrument Manufacturers

ddPCR, chip-based, and real-time PCR platforms

End-Users

Hospitals, diagnostic labs, CROs, CDMOs, pharma-biotech firms, forensic labs

This diverse mix creates opportunities for strategic partnerships, co-development deals, and vertical integration.

What’s Holding the Market Back?

1. Reimbursement and Regulatory Complexity Despite technological advances, limited reimbursement coverage, particularly for advanced PCR tests, discourages widespread adoption. For example, the US CMS policy revisions in 2023–2024 caused confusion around billing for transplant-related diagnostics, underscoring the need for policy clarity.

2. Competition from Emerging Technologies Alternatives like Next-Generation Sequencing (NGS), CRISPR diagnostics, and ELISA are gaining traction. While PCR remains a gold standard, these methods offer greater scalability, faster throughput, and in some cases, lower operational costs.

3. Labor-Intensive Workflow and Standardization Issues Sample preparation and post-PCR analysis still involve manual steps, increasing time-to-result and introducing variability. There's a clear opportunity to innovate through automation and AI integration.

What Opportunities Can C-Level Executives Leverage?

1. Invest in Companion Diagnostics RT-PCR-based companion diagnostics are critical for pharma firms developing targeted therapies. By embedding these diagnostics into drug development pipelines, companies can accelerate regulatory approvals and boost patient stratification precision.

2. Explore Untapped Markets Emerging economies in Southeast Asia, Latin America, and parts of Africa offer immense opportunity. Strategic local partnerships and distribution models can help overcome infrastructure and cost barriers.

3. Adopt Platform Thinking Building scalable PCR platforms that integrate AI, cloud data, and IoT can revolutionize disease monitoring. This will create long-term value for health systems and open recurring revenue streams via software and data analytics.

Conclusion: Precision Diagnostics Is the Next Frontier

As healthcare increasingly moves toward precision, decentralization, and real-time decision-making, digital and real-time PCR technologies are central pillars. However, success in this market depends not only on technological superiority but on strategic alignment—from regulatory navigation and reimbursement advocacy to platform innovation and global expansion.

For More information, Inquire Now.

[factmrblog1]

Genetic Research Driving PCR Growth with Biotechnology Innovations

The global polymerase chain reaction (PCR) market is experiencing robust growth, with its valuation estimated at $6.2 billion in 2024 and projected to reach $16 billion by 2034, achieving a compound annual growth rate (CAGR) of 10%. PCR, a cornerstone of molecular diagnostics, has transformed healthcare by enabling rapid and accurate detection of diseases. Drawing from FactMR’s market analysis, this blog explores the drivers, challenges, innovations, and future prospects of the PCR market.

What is Polymerase Chain Reaction?

Polymerase chain reaction (PCR) is a laboratory technique used to amplify DNA segments, producing millions of copies from a single strand. This enables detailed analysis of genetic material, making PCR critical for diagnosing infectious diseases, genetic disorders, and cancers. Variants like real-time PCR (qPCR) and digital PCR (dPCR) enhance its precision and applicability in research, clinical diagnostics, and forensics.

PCR’s significance was underscored during the COVID-19 pandemic, where qPCR became the gold standard for detecting SARS-CoV-2 due to its high sensitivity and specificity. Its applications extend beyond diagnostics to include genetic research, forensic analysis, and biotechnology.

Key Market Drivers

The PCR market’s growth is driven by the increasing prevalence of infectious diseases and genetic disorders. Conditions like sexually transmitted infections, respiratory diseases, and hepatitis are boosting demand for PCR-based diagnostics. The technique’s ability to detect pathogenic DNA with high accuracy makes it indispensable in clinical settings.

Technological advancements are another key driver. Innovations like qPCR and dPCR have improved the speed, accuracy, and scalability of PCR tests. The development of portable, point-of-care PCR devices, such as Nuclein’s ‘Nuclein Anywhere’ test, has expanded access to diagnostics, particularly in home-based settings. FactMR notes that the rising adoption of these advanced systems is fueling market growth.

Government and private investments in healthcare and pharmaceutical R&D are also significant. Increased funding for developing rapid diagnostic kits, such as RT-qPCR for SARS-CoV-2 detection, is driving sales of PCR products. The expansion of healthcare infrastructure in developing economies further supports demand for clinical PCR solutions.

Regional Insights

North America, particularly the United States, dominates the PCR market, accounting for 45.6% of the North American market share by 2034. The region’s advanced healthcare infrastructure, high adoption of cutting-edge diagnostics, and significant R&D funding drive growth. The U.S. benefits from rising awareness of PCR products and their integration into clinical and research applications.

Japan is an emerging market in East Asia, driven by growing awareness among healthcare professionals of gene-based diagnostics. Public-private partnerships to develop novel PCR technologies are expected to accelerate growth in the region. Other regions, including Europe and Asia Pacific, are also seeing increased adoption due to expanding healthcare systems and research activities.

Challenges in the Market

The high cost of advanced PCR technologies, such as qPCR and dPCR, is a significant barrier. FactMR reports that qPCR devices range from $4,000 to $13,000 or more, while dPCR systems are even pricier. These costs limit adoption in developing economies, where budget constraints are common.

Another challenge is the complexity of PCR systems, which require skilled personnel and sophisticated infrastructure. This can hinder their use in resource-limited settings. Additionally, competition from alternative diagnostic methods, such as next-generation sequencing (NGS), may impact the PCR market in certain applications.

Innovations and Trends

Innovation is transforming the PCR market. Companies like SAGA Diagnostics are leveraging dPCR for non-invasive cancer detection, with products like ‘SAGAsafe’ enabling accurate diagnosis of multiple cancer types. Similarly, advancements in RT-qPCR kits have improved the detection of viral variants, maintaining their relevance post-COVID.

The development of portable and automated PCR systems is a key trend. Devices like Anitoa Systems’ MAx16 and Bio-Rad’s CFX Opus 96 Dx System offer rapid, user-friendly diagnostics, making PCR accessible in diverse settings. These innovations align with the growing demand for point-of-care and home-based testing.

Opportunities for Growth

The PCR market offers significant opportunities, particularly in developing economies where healthcare infrastructure is expanding. The rising prevalence of chronic and infectious diseases creates a steady demand for PCR diagnostics. Companies investing in affordable, portable PCR solutions can tap into these markets.

Collaborations between diagnostic companies and healthcare providers can also drive growth. By developing tailored PCR solutions for specific diseases, manufacturers can address unmet needs and expand their market presence. FactMR highlights that the increasing focus on early disease detection and genetic research will further boost demand.

Future Outlook

With a projected valuation of $16 billion by 2034, the PCR market is set for strong growth. Its critical role in diagnostics, coupled with ongoing innovations, ensures its relevance in healthcare and research. As global health challenges evolve, PCR will remain a cornerstone of molecular diagnostics, driving advancements in disease detection and treatment.

Conclusion

The PCR market’s rapid growth reflects its transformative impact on diagnostics and research. With a CAGR of 10% and a projected valuation of $16 billion by 2034, it offers immense potential for innovation and expansion. As technology advances and healthcare needs grow, PCR will continue to shape the future of medical diagnostics.

[heathcareforallworld]

Trends and Projections for the Taq DNA Polymerase Market

The Taq DNA Polymerase Market is witnessing significant growth due to the increasing demand for polymerase chain reaction (PCR) technologies in various fields such as medical diagnostics, biotechnology, and forensic science. As the backbone of PCR, Taq DNA polymerase is indispensable for amplifying DNA sequences, making it a crucial component in research and clinical laboratories worldwide. This article delves into the market size, share, industry trends, and forecasts for the Taq DNA polymerase market through 2032.

Market Overview

Taq DNA polymerase is a thermostable enzyme extracted from the bacterium Thermus aquaticus, which is capable of withstanding high temperatures required for PCR. This enzyme's ability to replicate DNA sequences efficiently and accurately under thermal cycling conditions has revolutionized molecular biology and genetic research.

Market Size and Share

Taq dna polymerase Market Size was estimated at 1.6 (USD Billion) in 2023. The Taq Dna Polymerase Market Industry is expected to grow from 1.69(USD Billion) in 2024 to 2.53 (USD Billion) by 2032. The taq dna polymerase Market CAGR (growth rate) is expected to be around 5.19% during the forecast period (2024 - 2032).

North America currently holds the largest market share, accounting for over 40% of the global market. This dominance is attributed to the region's well-established biotechnology and pharmaceutical industries, extensive research activities, and the presence of key market players. Europe follows closely, with significant contributions from countries like Germany, the UK, and France. The Asia-Pacific region is expected to witness the fastest growth, driven by increasing investments in biotechnology, rising healthcare expenditure, and growing awareness about molecular diagnostics.

Industry Trends

Technological Advancements: The Taq DNA polymerase market is benefiting from continuous technological innovations. The development of high-fidelity and fast-cycling Taq polymerases has enhanced the efficiency and accuracy of PCR, expanding its applications in various fields.

Rising Demand for Molecular Diagnostics: The increasing prevalence of infectious diseases, genetic disorders, and cancer has fueled the demand for molecular diagnostics. Taq DNA polymerase plays a crucial role in diagnostic assays, including COVID-19 testing, driving market growth.

Expansion of Personalized Medicine: The shift towards personalized medicine, which relies on genetic profiling for tailored treatments, is boosting the demand for Taq DNA polymerase. PCR-based techniques are integral to genetic testing and the development of personalized therapies.

Growing Research and Development Activities: The surge in research and development activities in genomics, proteomics, and biotechnology is propelling the demand for Taq DNA polymerase. Government and private sector investments in research are further stimulating market growth.

Increased Forensic Applications: The application of PCR in forensic science for DNA profiling and criminal investigations is expanding. Taq DNA polymerase is a vital tool in forensic labs, aiding in the accurate identification of individuals from biological samples.

Market Drivers

Advancements in PCR Technology: Innovations such as real-time PCR (qPCR) and digital PCR (dPCR) are driving the adoption of Taq DNA polymerase. These advanced techniques offer higher sensitivity, specificity, and quantification capabilities, broadening the scope of PCR applications.

Growing Biotechnology Industry: The biotechnology industry's rapid growth, coupled with increasing investments in genetic research, is boosting the demand for Taq DNA polymerase. The enzyme is essential for various applications, including cloning, sequencing, and gene expression analysis.

Increasing Prevalence of Genetic Disorders: The rising incidence of genetic disorders and the need for early diagnosis and treatment are driving the demand for PCR-based diagnostic tests. Taq DNA polymerase is a key component in these tests, contributing to market growth.

COVID-19 Pandemic: The COVID-19 pandemic has significantly increased the demand for PCR testing, highlighting the importance of Taq DNA polymerase. The enzyme's critical role in detecting the virus has led to a surge in production and sales.

Challenges

High Cost of Enzyme Production: The production of high-quality Taq DNA polymerase involves complex processes and significant investment, leading to high costs. This can be a barrier for small-scale laboratories and research institutions.

Competition from Alternative Enzymes: The market faces competition from alternative DNA polymerases with improved properties, such as higher fidelity and faster cycling times. The development and adoption of these alternatives can impact the market share of Taq DNA polymerase.

Stringent Regulatory Requirements: The stringent regulatory requirements for the approval and commercialization of diagnostic and research products can pose challenges for market players. Compliance with these regulations can be time-consuming and costly.

Market Forecast (2024-2032)

The Taq DNA polymerase market is poised for substantial growth over the forecast period. Key factors contributing to this growth include:

Expanding Applications in Diagnostics and Research: The ongoing advancements in PCR technology and the expanding applications in diagnostics and research are expected to drive market growth. The enzyme's versatility and reliability make it indispensable in various fields.

Increasing Investments in Biotechnology: The increasing investments in biotechnology and genetic research by governments, private companies, and research institutions will propel the demand for Taq DNA polymerase. The enzyme's role in groundbreaking research and development activities will continue to drive market expansion.

Emerging Markets in Asia-Pacific: The Asia-Pacific region is expected to witness the fastest growth, driven by rising healthcare expenditure, increasing biotechnology investments, and growing awareness about molecular diagnostics. Countries like China, India, and Japan are key markets to watch.

Adoption of Personalized Medicine: The shift towards personalized medicine and the growing demand for genetic testing will boost the market for Taq DNA polymerase. The enzyme's critical role in genetic analysis and the development of personalized therapies will drive its adoption.

Conclusion

The Taq DNA polymerase market is on a robust growth trajectory, driven by technological advancements, increasing demand for molecular diagnostics, and expanding research and development activities. Key players in the industry are focusing on product development, strategic collaborations, and expanding their geographical presence to capitalize on the growing demand for Taq DNA polymerase.

[marketresearchnews1242]

Global Digital PCR Market Competitions From Opponents Research 2022

The healthcare vertical is witnessing an ever-increasing need for automation, thereby leading to quick service provision for bridging existential gap between medical professionals and users. One of the most profit-making healthcare technologies is Artificial Intelligence, which enables automated service provision. The application areas include collection, management, and processing a huge quantity of user data. This would be the behaviour of the Digital PCR Market in the forecast period. Digital PCR Market Share, Growth, Trends And Forecast To 2031| value of US$ 347 Mn at a CAGR of 9.3%

The global digital PCR market is worth more than US$ 132 Mn at present. Demand for digital PCR is estimated to surge at a CAGR of 9.3% with an estimated value of US$ 347 Mn by 2031. User-friendly instruments of digital PCR, novel applications of digital PCR, and automation in advanced digital PCR instruments are some of the key trends in the market.

Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/20476

Digital PCR, or dPCR, is a new quantitative PCR method that enables ultrasensitive and reproducible detection as well as quantification of nucleic acid. It is an alternative method to conventional real-time qPCR, where the amplification reaction remains same but the method of quantifying the target sample differs.

Rising awareness about advanced molecular diagnostics is set to enhance the utilization of dPCR. Molecular diagnostics, specifically nucleic acid-based techniques for the detection of infectious diseases are rapidly growing approaches in clinical diagnostic laboratories. These techniques have been evolving since their development, including advances in digital PCR technologies that can now aid in the precise diagnosis of life-threatening diseases such as cancer and Ebola. There are several digital PCR-based diagnostic kits and assays for multiple diseases that have been introduced in molecular diagnosis over the previous decade.

Increasing global funding in research & development is adjacent to driving the demand of digital PCRs. Application of PCR-based techniques in drug discovery, genomics, and personalized medicine has augmented its penetration to reach the field of point-of-care molecular diagnostics. To address the global disease burden, there is a recent surge in the expenditure that contributes to the research and development of disease-related scientific studies. The trend is also encouraging molecular diagnostic manufacturers to invest more and support ongoing research in government and non-profit organizations.

Additionally, the National Institute of Health (NIH) has started the precision medicine initiative to address the issues and time associated with disease diagnosis and treatment. As opposed to the ‘one-size-fits-all’ treatment approach, precision medicine is an innovative approach that considers variety in people’s genes, environments, and lifestyles. Implementation of precision medicine has led to new discoveries and several FDA approvals for treatments pertaining to specific characteristics of an individual.

Company Profiles:

Bio-Rad Laboratories, Inc.

Agilent Technologies

Thermo Fisher Scientific Inc.

Fluidigm Corp

Formulatrix, Inc

JN Medsys

ADJUST

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/20476

Key Takeaways from Market Study

By product, instruments are expected to hold over 70% market value share by the end of 2031, primarily because of the presence of key market players for production worldwide.

Based on application, basic research is leading with nearly 35% market share, owing to extensive research opportunities in infection diagnosis and drug discovery.

Research institutes dominated the end-user segment with a share of around 69.4% in 2020, due to increasing number of molecular biology companies focusing on infection diagnostics after the COVID-19 pandemic.

By region, North America is slated to be the largest market with a value share of 35% by the end of the forecast period (2021 to 2031).

“Advancements in technology and application of digital PCR in drug discovery are anticipated to propel demand for as a measure for disease detection and prevention,” says an analyst of Persistence Market Research.

Market Competition

Acquisitions, mergers, expansions, and product launches are the key strategies adopted by manufacturers to increase their consumer base across geographies.

On October 28, 2021, Bio-Rad Laboratories projected a growth rise in Q3 revenue after acquisition of dPCR maker, Dropworks.

On September 20, 2021, Thermofisher launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.

On January 14, 2019, Qiagen NV agreed to acquire certain molecular testing assets from Formulatrix Inc., including the CONSTELLATION® series of instruments.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the digital PCR market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.

The research study is based on the product (instruments, consumables, and service), application (clinical diagnostics, basic research, applied research, and forensic testing), and end user (pharmaceutical companies, research institutes, forensic labs and agriculture companies), across seven key regions of the world.

Key geographies evaluated in this report are: North America – U.S, Canada Europe – France, Germany, Italy, Spain, and the UK, Eastern Europe, CIS APAC – China, India, Japan, Australia, Others Latin America – Argentina, Brazil, Others

Access Full Report@ https://www.persistencemarketresearch.com/checkout/20476

Key Questions Answered in This Report.

What will the Market growth rate in Future?

What are the key factors driving the global Market?

Who are the key manufacturers in Market space?

What are the opportunities and threats faced by the vendors in the global industry?

What are sales, revenue, and price analysis by regions of industry?

About Us: Persistence Market Research

Contact Us:

Persistence Market Research           Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – sales@persistencemarketresearch.com

[rahulg1122]

Future Growth Analysis of Neurodiagnostics Market

According to the new market research report "Neurodiagnostics Market by Product (Diagnostic & Imaging Systems (MRI, Ultrasound), Clinical Testing (PCR, NGS), Reagents & Consumables), Disease Pathology (Epilepsy, Stroke), End User, and Region - Global Forecast to 2024", published by MarketsandMarkets™, the Neurodiagnostics Market is expected to reach USD 8.4 billion by 2024 from USD 5.9 billion in 2019, at a CAGR of 7.3%.

Browse in-depth TOC on "Neurodiagnostics Market"

189 – Tables

28 – Figures  

239 – Pages 

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=229090425

The demand for neurodiagnostic products is expected to grow mainly due to factors such as the increasing prevalence of neurological disorders & diseases, technological advancements, growing patient emphasis on effective & early disease diagnosis, the growing number of diagnostic centers & hospitals, and the use of biomarker profiling for disease diagnostics. These factors have prompted market players to improve and strengthen their current manufacturing and distribution capabilities—especially in emerging markets, which are expected to witness the highest growth.

The diagnostic imaging systems segment accounted for the largest share of the Neurodiagnostics Market, by product, in 2018.

Based on the product, the market is segmented into diagnostic imaging systems, clinical diagnostic instruments, and reagents and consumables. The diagnostic imaging systems segment accounted for the largest share of the market in 2018. The increasing incidence and prevalence of neurological disorders and growing R&D in the field of cerebral and spinal disorders are the major factors driving the growth of this segment.

The hospitals & surgical centers segment accounted for the largest share of the Neurodiagnostics Market, by end-user, in 2018

On the basis of end-user, the market is segmented into hospitals & surgical centers, diagnostic laboratories & imaging centers, neurology centers, ambulatory care centers (ACCs), and research laboratories & academic institutes.

In 2018, hospitals & surgical centers accounted for the largest share of the Neurodiagnostics Market, mainly due to the financial capabilities of hospitals to purchase expensive equipment, such as neurodiagnostic devices.

Get 10% Customization on this Research Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=229090425

North America accounted for the largest share of the Neurodiagnostics Market in 2018

North America accounted for the largest share of the market in 2018, followed by Europe. This can primarily be attributed to the presence of a highly developed healthcare system, high adoption of innovative neurodiagnostic devices among medical professionals, and the full availability of advanced neurodiagnostic devices.

Some of the prominent players in the Neurodiagnostics Market include GE Healthcare (US), Siemens Healthineers (Germany), Philips Healthcare (Netherlands), Hitachi, Ltd. (Japan), Canon, Inc. (Japan), Lifelines Neuro Company, LLC (US), Natus Medical Incorporated (US), Hoffman-La Roche AG (Switzerland), FUJIFILM Holdings Corporation (Japan), Mitsar Co., Ltd. (Russia), Advanced Brain Monitoring (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories (US), QIAGEN N.V. (Netherlands), Nihon Kohden Corporation (Japan), ANT Neuro (Netherlands), Fonar Corporation (US), Fujirebio (Japan), DRG Instruments GmbH (Germany), Tecan Trading AG (Switzerland), Motion Lab Systems, Inc. (US), Rigaku Corporation (Japan), Neusoft Medical Systems Co., Ltd. (US), ELMIKO MEDICAL Sp. Z o.o. (Poland) and Ridge Diagnostics (US).

Browse Related Reports:

Next-generation Sequencing Market by Product (NOVASEQ, NEXTSEQ, SEQUEL, NANOPORE), Consumables, Bioinformatics, Services (EXOME, RNA, DENOVO), Technology (ION, SMRT), Application (Diagnostics, Cancer), End User, Region - Global Forecast to 2025

Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents, Software, Services), Application (Clinical, Oncology, Forensics), End-user (Hospitals, Diagnostic Labs, Academia, Pharma-Biotech, CRO) - Global Forecast to 2024

[mitalipingale]

https://tannda.net/read-blog/73424_digital-pcr-dpcr-and-real-time-pcr-qpcr-market-share-overview-competitive-analys.html

The Digital PCR (dPCR) and Real-time PCR (qPCR) Market in 2023 is US$ 8.5 billion, and is expected to reach US$ 15.76 billion by 2031 at a CAGR of 8.00%.

[research-89]

https://writeupcafe.com/digital-pcr-dpcr-and-real-time-pcr-qpcr-market-overview-size-share-and-forecast-2031/

[sandlerresearch]

Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospitals & Diagnostic Centers, Pharma Biotech, CROs) - Global Forecast to 2025 published on

https://www.sandlerresearch.org/digital-pcr-dpcr-and-real-time-pcr-qpcr-market-by-product-instruments-reagents-consumables-software-services-application-clinical-research-forensic-end-user-hospitals-diagnostic-c.html

Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospitals & Diagnostic Centers, Pharma Biotech, CROs) - Global Forecast to 2025

“The dPCR and qPCR market is projected to grow at a CAGR of 9.0% during the forecast period (2020–2025).”

The global dPCR and qPCR market size is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0%. The growth of this market is driven majorly by factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project. On the other hand, high instrument costs—especially that of dPCR—and the technical limitations of PCR are restraining market growth.

“By application, the clinical applications segment (of qPCR) is expected to grow at the highest CAGR during the forecast period.”

Based on application, the qPCR market is segmented into clinical applications, research applications, and forensic applications. The clinical applications segment is expected to register the highest growth during the forecast period. The key factors driving the market growth include the growing usage of qPCR in disease diagnosis, rising incidence of infectious & genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment..

“By end-user, the hospitals and diagnostics centers segment dominated the dPCR market in 2019.”

Based on end-user, the dPCR market is segmented into Hospitals and Diagnostic Centers, Research Laboratories and Academic Institutes, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, and Forensic Laboratories. The Hospitals and Diagnostic Centers segment accounted for the largest share of the dPCR market in 2019, primarily due to the growing demand for early and efficient disease diagnosis and treatment, increasing number of dPCR product launches for diagnostic applications, benefits offered by dPCR in disease diagnosis (as compared to other PCR technologies), and growing public awareness related to the benefits offered by dPCR in disease diagnosis.

“Asia Pacific dPCR and qPCR market is expected to witness the highest growth during the forecast period.”

The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period, primarily due to the ongoing expansion & modernization of the healthcare infrastructure in emerging Asian countries; increasing number of research projects in China, India, and Japan in the field of genomics and cancer; the rising trend of clinical research being outsourced to Asia-based CROs by leading drug manufacturing companies; and continuous government support for genomics-based research activities in emerging Asia Pacific countries.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–45%, Tier 2–34%, and Tier 3–21%

By Designation: D-level–14%, C-level–10%, and Others–78%

By Region: North America–31%, Europe–33%, Asia Pacific–19%, RoW-18%

Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland) are the key players operating in this market. Other prominent players are Abbott Laboratories (US), Agilent Technologies (US), Analytik Jena AG (Switzerland), Becton Dikinson and Company (US), bioMérieux SA (France), Danaher Corporation (US), Eppendorf (Germany), Fluidigm Corporation (US), Merck KGaA  (Germany), QIAGEN N.V.  (Netherlands), Takara Bio (Japan), Meridian Bioscience (US), Promega Corporation (US), Enzo Life Sciences, Inc. (US), Bioneer (South Korea), ELITech Group (France), and Quidel Corporation (US).

Research Coverage:

The report analyzes the dPCR and qPCR market and aims at estimating the market size and future growth potential. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a more significant share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the dPCR and qPCR market

Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the dPCR and qPCR market

Market Development: Comprehensive information on lucrative emerging regions

Market Diversification: Exhaustive information about new systems, growing geographies, and recent developments in the global dPCR and qPCR market

Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and services of leading players in the dPCR and qPCR market

[wiseguy05]

Global Metal Credit Cards Market By Type, By Application, By Segmentation, By Region, and By Country 2020-2026

Metal credit cards are credit cards made from metal materials. It is heavier than the common plastic metal card, the production process is more complicated, and generally has more added value. Metal credit cards are often tailored to the customer.

Also Read: https://www.openpr.com/news/2094042/covid-19-impact-on-global-metal-credit-cards-market-dynamics

 Metal credit cards aren’t just for the wealthy with sky-high annual fees. Now three no-annual-fee credit cards carry some heft when plunked down on a restaurant table. Currently, there are many players in this market. Composecure, CPI Card Group, Gemalto, X-Core, G&D and some others are playing important roles in Metal Credit Cards industry. The market is relatively concentrated for now and is seeing to be more concentrated.In market, revenue of Metal Credit Cards in North America will increase to be 1402 M USD in 2025 from 248 M USD in 2018, which is the biggest consumption area in current market pattern. Europe ranks the second largest consumption area, with revenue of 173 USD in 2018. There are many different types of Metal Credit Cards. The market can be segmented into: Hybrid Metal Card, Veneer Metal Card, Full Metal Card and Others. Hybrid Metal Card Type is the most commonly used and efficient types and took 62.27% market share in 2018. By application, Standard Cards is the largest consumer group, with market share of 86.69% in 2018. The global Metal Credit Cards market is valued at 510 million US$ in 2018 and will reach 2918.6 million US$ by the end of 2025, growing at a CAGR of 24.4% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Metal Credit Cards market based on company, product type, end user and key regions.

Also Read: https://www.openpr.com/news/969652/Rice-Wine-Global-Market-Key-Players-SAVEUR-Kuaijishan-Jinfeng-Wine-PAGOOA-Nuerhong-Analysis-and-Forecast-to-2025.html

 This report studies the global market size of Metal Credit Cards in key regions like North America, Europe, China and South America, focuses on the consumption of Metal Credit Cards in these regions. This research report categorizes the global Metal Credit Cards market by top players/brands, region, type and end user. This report also studies the global Metal Credit Cards market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Also Read: http://www.marketwatch.com/story/specialty-chemicals-market-2021-industry-size-share-price-trend-and-forecast-to-2026-2021-01-21

 The following manufacturers are covered in this report, with sales, revenue, market share for each company: Composecure CPI Card Group Gemalto X-Core G&D Goldpac Valid ...

Metal Credit Cards market size by Type Full Metal Card Hybrid Metal Card Veneer Metal Card Others

Also Read: http://www.marketwatch.com/story/digital-pcr-dpcr-and-real-time-pcr-qpcr-2021-market-estimation-dynamics-outlook-research-trends-and-forecasts-to-2025-2021-01-22

 In 2018, Hybrid Metal Card accounted for a major share of 64% in the global Metal Credit Cards market. And this product segment is poised to reach 1842 M USD by 2025 from 498 M USD in 2019.

Metal Credit Cards market size by Applications Standard Cards Custom Cards

In Metal Credit Cards market, Standard Cards segment holds an important share in terms of application, and it is expected to reach a volume of 26166 (K Units) by 2025, at a CAGR of 26.4% during 2018 and 2025. It means that Metal Credit Cards will be promising in the Standard Cards field in the next couple of years.

Market size by Region North America United States Canada Mexico Europe Germany France UK Italy Russia Asia-Pacific China Japan South Korea India Australia Indonesia Thailand Malaysia Philippines Vietnam Central & South America Brazil Middle East & Africa Turkey GCC Countries Egypt South Africa

The study objectives of this report are: To study and analyze the global Metal Credit Cards market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025. To understand the structure of Metal Credit Cards market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Metal Credit Cards companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development. To project the value and sales volume of Metal Credit Cards submarkets, with respect to key regions. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Metal Credit Cards are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

ALSO READ: http://www.marketwatch.com/story/hot-water-storage-tank-industry-production-and-demand-competition-news-and-trends-forecasts-to-2025-2021-01-20

 About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

 Contact Us:

NORAH TRENT                                                      

sales@wiseguyreports.com       

Ph: +162-825-80070 (US)                          

Ph: +44 2035002763 (UK)  

[marketresearchnewsdbmr]

QPCR and dPCR Market by Types, Risk Factor, Drivers, Market Size, Demand, Opportunities, Shares | Enzo Life Sciences, Inc.,; Fluidigm Corporation; Danaher; Abbott; Merck KGaA

QPCR and dPCR Market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global QPCR and dPCR market.Few of the major competitors currently working in the qPCR and dPCR market are Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc.; QIAGEN; Takara Bio Inc.; Agilent Technologies, Inc.; bioMérieux SA; Fluidigm Corporation; Danaher; Abbott; Merck KGaA; Promega Corporation; BD; Meridian Bioscience, Inc.; Analytik Jena AG; Eppendorf AG; BIONEER COPORATION; Enzo Life Sciences, Inc.,; Quantabio; Formulatrix; JN Medsys; Thomas Scientific and Biomeme, Inc.

Global qPCR and dPCR Market is expected to rise from its initial estimated value of USD 3.64 billion in 2018 to a projected value of USD 7.14 billion by 2026, registering a CAGR of 8.78% in the forecast period of 2019-2026.

Get Exclusive Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-qpcr-and-dpcr-market

qPCR (Quantitative Polymerase Chain Reaction), also known as Real-Time Polymerase Chain Reaction can be defined as a diagnostic technique/method. This method involves the monitoring of DNA molecule in real-time rather than at the concluding stage in conventional PCR techniques.

dPCR (Digital Polymerase Chain Reaction) is a quantitative method of measuring the presence/amount of DNA and RNA present in a particular sample. Though, the results of this method are more precise and correct, lack of knowledge regarding the method can prove to be a factor that results in incorrect results.

Market Drivers: Global qPCR and dPCR Market

Increasing adoption of qPCR and qPCR in diagnostics which has been a result of rising prevalence of infectious and genetic diseases

Innovations & advancements related to technology and increased investments in the market from private & public sectors; these factors are expected to drive the market growth

Market Restraints:

Factors such as high costs, lack of knowledge and skills for professionals are one of the major factors that act as a restraint to the market growth

Global QPCR and dPCR Market Size, Status and Forecast 2019 – 2020

1 Market Overview

2 Manufacturers Profiles

3 Global QPCR and dPCR Sales, Revenue, Market Share and Competition by Manufacturer

4 Global QPCR and dPCR Market Analysis by Regions

5 North America QPCR and dPCR by Countries

6 Europe QPCR and dPCR by Countries

7 Asia-Pacific QPCR and dPCR by Countries

8 South America QPCR and dPCR by Countries

9 Middle East and Africa QPCR and dPCR by Countries

10 Global QPCR and dPCR Market Segment by Type

11 Global QPCR and dPCR Market Segment by Application

12 QPCR and dPCR Market Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendixes

Access Detailed TOC@ https://www.databridgemarketresearch.com/toc/?dbmr=global-qpcr-and-dpcr-market

The Report Highlights

Historic and forecasted QPCR and dPCR market size in terms of revenues & unit sales, average selling price, growth rates, and company market shares.

Highlights and compares key application/product categories for growth trends and revenue forecast.

QPCR and dPCR Market size, revenue and unit sales according to each region

Cross category comparison – Growth and revenue comparison for product categories, historic and forecast through 2026.

QPCR and dPCR Market share of top key players

Current trends and recent Developments

Scope of the QPCR and dPCR Market Report

QPCR and dPCR Market (Actual Period: 2017-2018, Forecast Period: 2019-2020)

QPCR and dPCR Market – Size, Growth, Forecast

Analysis by Type:

Regional Analysis – Actual Period: 2017-2018, Forecast Period: 2019-2020

QPCR and dPCR Market – Size, Growth, Forecast

QPCR and dPCR Market Analysis by Type

Access Full Reports @ https://www.databridgemarketresearch.com/reports/global-qpcr-and-dpcr-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com